Efficacy of SGLT2 Inhibitors in Adults With Sepsis
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorHospital Authority, Hong Kong
About this trial
Goal of this clinical trial is to examine the safety and efficacy of SGLT2 inhibitors on the clinical outcomes in patients with sepsis. Main study outcomes are as follows:
(i) Primary objective is to examine the efficacy and safety of SGLT2 inhibitors on clinical outcomes in patients with sepsis.
(ii) Secondary objective is to examine the effect of SGLT2 inhibitors on inflammatory markers in patients with sepsis.
Eligibility criteria
Qualifiers
Aged 18 years or above
New onset of sepsis within 48 hours defined according to the Sepsis-3 criteria. (≥2 SOFA)
Provision of signed and dated informed consent form from participant or surrogate
Ability to take and adhere to oral and enteral medication regimen
Disqualifiers
Current or recent use of SGLT2 inhibitors (within 12wks prior to randomization)
Impaired renal function
Clinically unstable or in refractory hypotension
History of ketoacidosis
Trial design
Treatments tested in this trial
- Empagliflozin 10 MG
- Placebo
Treatment groups
60 Participants
are divided into 2 treatment groupsLocations
34/F Main Clinical Block and Trauma Centre, Prince of Wales Hospital, Shatin, New Territories, Hong Kong0000, Hong KongHong Kong, Hong Kong
Adult Intensive Care Unit, Queen Mary Hospital, 102 Pok Fu Lam Road, Hong Kong0000, Hong KongHong Kong, Hong Kong
The University of Hong Kong00, Hong Kong Hong Kong
Sponsors and collaborators
Hospital Authority, Hong Kong
Lead sponsor
Chinese University of Hong Kong
Collaborator
Source ClinicalTrials.gov